AU2013243857A1 - Methods for increasing CFTR activity - Google Patents

Methods for increasing CFTR activity Download PDF

Info

Publication number
AU2013243857A1
AU2013243857A1 AU2013243857A AU2013243857A AU2013243857A1 AU 2013243857 A1 AU2013243857 A1 AU 2013243857A1 AU 2013243857 A AU2013243857 A AU 2013243857A AU 2013243857 A AU2013243857 A AU 2013243857A AU 2013243857 A1 AU2013243857 A1 AU 2013243857A1
Authority
AU
Australia
Prior art keywords
cftr
subject
depth
mucociliary clearance
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013243857A
Other languages
English (en)
Inventor
Mark Dransfield
Steven M. ROWE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of AU2013243857A1 publication Critical patent/AU2013243857A1/en
Priority to AU2018200192A priority Critical patent/AU2018200192B9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2013243857A 2012-04-06 2013-03-15 Methods for increasing CFTR activity Abandoned AU2013243857A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018200192A AU2018200192B9 (en) 2012-04-06 2018-01-10 Methods for increasing CFTR activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621043P 2012-04-06 2012-04-06
US61/621,043 2012-04-06
PCT/US2013/032268 WO2013151758A2 (en) 2012-04-06 2013-03-15 Methods for increasing cftr activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018200192A Division AU2018200192B9 (en) 2012-04-06 2018-01-10 Methods for increasing CFTR activity

Publications (1)

Publication Number Publication Date
AU2013243857A1 true AU2013243857A1 (en) 2014-10-16

Family

ID=49301152

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013243857A Abandoned AU2013243857A1 (en) 2012-04-06 2013-03-15 Methods for increasing CFTR activity
AU2018200192A Ceased AU2018200192B9 (en) 2012-04-06 2018-01-10 Methods for increasing CFTR activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018200192A Ceased AU2018200192B9 (en) 2012-04-06 2018-01-10 Methods for increasing CFTR activity

Country Status (8)

Country Link
US (2) US20150065539A1 (https=)
EP (1) EP2833885A4 (https=)
JP (1) JP6525203B2 (https=)
CN (1) CN104619321A (https=)
AU (2) AU2013243857A1 (https=)
CA (1) CA2869257A1 (https=)
HK (1) HK1206995A1 (https=)
WO (1) WO2013151758A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
MX2011001782A (es) 2008-08-13 2012-02-08 Vertex Pharma Composicion farmaceutica y su administracion.
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2011030163A1 (en) * 2009-09-12 2011-03-17 Reckitt Benckiser Llc Use of guaifenesin for inhibiting mucin secretion
KR101924162B1 (ko) * 2010-03-15 2018-11-30 버지니아 커먼웰스 유니버시티 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
EP3037415A1 (en) * 2010-03-19 2016-06-29 Vertex Pharmaceuticals Inc. Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
RS56096B1 (sr) * 2011-05-18 2017-10-31 Concert Pharmaceuticals Inc Deuterisani derivati ivakaftora

Also Published As

Publication number Publication date
HK1206995A1 (en) 2016-01-22
US10300052B2 (en) 2019-05-28
EP2833885A4 (en) 2015-12-16
JP6525203B2 (ja) 2019-06-05
AU2018200192B9 (en) 2019-07-25
CA2869257A1 (en) 2013-10-10
WO2013151758A2 (en) 2013-10-10
JP2015521157A (ja) 2015-07-27
CN104619321A (zh) 2015-05-13
EP2833885A2 (en) 2015-02-11
US20170266177A1 (en) 2017-09-21
US20150065539A1 (en) 2015-03-05
AU2018200192B2 (en) 2019-06-06
AU2018200192A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
RU2435585C2 (ru) Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких
Brand et al. Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis
US7524820B1 (en) Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology
US6462019B1 (en) Inhibitors of proteasomal activity and production for stimulating bone growth
Mero et al. A hyaluronic acid–salmon calcitonin conjugate for the local treatment of osteoarthritis: Chondro-protective effect in a rabbit model of early OA
Chai et al. Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model
Lin et al. The expectorant activity of naringenin
AU2018200192B9 (en) Methods for increasing CFTR activity
US10413583B2 (en) Synthetic substrates for enzymes that catalyze reactions of modified cysteines and related methods
Pankov et al. Cholesterol distribution in plasma membranes of β1 integrin-expressing and β1 integrin-deficient fibroblasts
Schultz et al. Pulmonary insulin-like growth factor I delivery from trehalose and silk-fibroin microparticles
CA2584195A1 (fr) Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
Jaehde et al. Quantification and visualization of the transport of octreotide, a somatostatin analogue, across monolayers of cerebrovascular endothelial cells
CA2288178A1 (en) Piperazine derivatives for treating bone deficit conditions
AU2006302591A1 (en) ApoE4 domain interaction inhibitors and methods of use thereof
EP1817039A2 (en) Treatment and prevention of epilepsy
Zhang et al. Effects of ephedrine on human nasal ciliary beat frequency
JP5283962B2 (ja) 医薬組成物
Remigius et al. Mechanistic appraisal of the effects of some protease inhibitors on ciliary beat frequency in a sequential cell culture system of human nasal epithelium
WO2023199010A1 (en) Treatment of muscle fibrosis
Reber et al. Intracellular changes in astrocytes and NG 108-15 neuroblastoma X glioma cells induced by advanced glycation end products
Duffya et al. Osteoclastogenesis Requires Primary Cilia Disassembly and Can Be Inhibited by Promoting Primary Cilia Formation Pharmacologically
JP6108569B2 (ja) 虚血性疾患の治療又は予防のための薬剤及びその利用
Alqahtani Development and application of in vitro approaches to assess the interactions of aerosolised drugs with pulmonary mucus
Ribeiro et al. Cystic fibrosis airway epithelial Ca2+ i signaling: the 7

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted